Aktiesnakken — Januar 2011
-
reelt set (i et efficient marked) burde markedet have taget højde for det allerede da aktierne blev indkøbt
-
jeg tror ikke der kommer det vilde udsalg
-
det der ligger i kortene for land er stigende udbytter
-
og den giver 5% nu!
-
genmab, positivt med dlbcl, spændende med den kliniske erfaring med arzerra
-
zalu er rykket ned i 2. geled
-
på stående fod pas mem mener det er april
-
den er priorieteret lavere end daratumumab, måske en indikation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind